plozalizumab (TAK-202)

News alerts, weekly reports and conference planners

Company:

Takeda

Drug class:

CCR2 receptor inhibitor

Related drugs:

‹

PF-04136309 (0)

›

almost2years

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (clinicaltrials.gov)

P1, N=22, Terminated, Millennium Pharmaceuticals, Inc. | Phase classification: P1b --> P1

almost 2 years ago

Phase classification • Combination therapy • Checkpoint inhibition • Metastases

BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

BRAF mutation • NRAS mutation • BRAF V600

Opdivo (nivolumab) • Yervoy (ipilimumab) • Ojemda (tovorafenib) • Entyvio (vedolizumab) • plozalizumab (TAK-202)

2years

A Systems Biology Approach for Investigating Significant Biomarkers and Drug Targets Common Among Patients with Gonorrhea, Chlamydia, and Prostate Cancer: A Pilot Study. (PubMed, Bioinform Biol Insights)

Three potential therapeutic compounds namely INCB3284, CCX915, and MLN-1202 were found to interact with up-regulated protein C-C chemokine receptor type 2 (CCR2) in protein-drug interaction analysis. The proposed biomarkers and therapeutic potential molecules could be investigated for potential pharmacological targets and activity in the fight against in patients with gonorrhea, chlamydia, and prostate cancer.

2 years ago

Journal

SLFN11 (Schlafen Family Member 11) • GATA6 (GATA Binding Protein 6) • APP (Amyloid Beta Precursor Protein) • KMT2B (Lysine Methyltransferase 2B) • MIR7 (MicroRNA 7) • CCR2 (C-C Motif Chemokine Receptor 2) • HIVEP1 (HIVEP Zinc Finger 1) • SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like) • DERL1 (Derlin 1) • MARCKS (Myristoylated Alanine Rich Protein Kinase C Substrate) • PRNP (Prion Protein) • PTGS1 (Prostaglandin-Endoperoxide Synthase 1) • SLC40A1 (Solute Carrier Family 40 Member 1)

plozalizumab (TAK-202)